Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
Patients must have received prior therapy other than surgery and must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
Prior cancer treatment must be completed at least  days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to =< grade  or baseline
Resolution of all toxic side effects from prior oncology treatments
Has recovered from the toxic effects of prior therapy to their clinical baseline
Recovered to Grade  from the effects (excluding alopecia) of any prior therapy for their malignancies
Patient must have recovered from any toxic effects of previous chemotherapy, targeted therapy or radiotherapy as judged by the investigator to ? grade 
Recovered from the toxic effects of prior therapy to < grade  toxicity per NCI CTCAE prior to study registration (except lymphopenia).
TREATMENT INCLUSION: Recovered from all acute non-hematologic toxic effects of all prior chemotherapy
Has not recovered to Grade ? from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy. Note: Subjects with Grade ? neuropathy is an exception and may enroll.
Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion
Has recovered from the toxic effects of prior therapy to their clinical baseline
Patients must be recovered to grade  from the effects (excluding alopecia) of any prior therapy for their malignancies
Patients must have recovered to =< grade  or stabilized from the toxic effects of any prior chemotherapy (except alopecia)
Prior cancer treatment (systemic therapy or radiation therapy) must be completed at least  weeks prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to grade =<  or baseline.
Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion
Patient must have recovered from acute toxic effects (? grade ) of previous cancer treatments prior to enrollment
Patients must have recovered from the effects of prior therapy
Recovered from all acute side-effects (except alopecia) related to previous systemic therapy
No chemotherapy, radiation, or major surgery within two weeks prior to first dose of study drug and/or recovered from the toxic side effects of that therapy, unless treatment is indicated due to progressive disease.
Recovered to Grade  or baseline from all toxic effects of previous therapy (except alopecia or neuropathy).
Patients must have recovered from the toxic effects of prior therapy at the time of initiation of the study drug unless toxicity is stable
Prior cancer treatment must be completed at least  days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ?grade  or to baseline prior to initiation of that therapy.
Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy; guidelines for this recovery period are dependent upon the specific therapeutic agent being used:\r\n* Patients who are less than  weeks from radiation therapy, unless progressive disease outside of the radiation field or  consecutive scans with disease progression or histopathologic confirmation of recurrent tumor\r\n* Patients who have received chemotherapy or bevacizumab =<  weeks (except for nitrosourea [ weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [ week]) prior to starting the study drug unless patients have recovered from side effects of such therapy\r\n* Patients who have received immunotherapy =<  weeks prior to starting the study drug unless patients have recovered from side effects of such therapy
Participants must have recovered to grade  or  or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)
Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy; guidelines for this recovery period are dependent upon the specific therapeutic agent being used
Radiation therapy (within  weeks of Study Day  or has not recovered from the toxic effects of such therapy).
Gliadel Wafer (within  months of Study Day , or has not recovered from the toxic effects of such therapy).
Immunotherapeutic agents, vaccines, or monoclonal antibody therapy (within  weeks of Study Day  or has not recovered from the toxic effects of such cancer therapy).
Temozolomide or other chemotherapy (within  weeks of Study Day  or  weeks for nitrogen mustards, or has not recovered from the toxic effects of such cancer therapy).
Surgical resection of brain tumor (within  weeks of Study Day  or has not recovered from acute side effects of such therapy except for neurological effects).
Recovered to grade  from the effects (excluding alopecia) of any prior therapy for their malignancies
Must have recovered from the acute toxic effects of all prior therapy prior to registration for this study to grade  or less
Subjects must have recovered from the toxic effects of any prior chemotherapy to < grade  (except alopecia)
Treated with immunotherapeutic agents, vaccines, or monoclonal antibody (Mab) therapy within  weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Treated with alkylating agents within  weeks ( weeks for nitrosoureas) before enrollment or treated within  week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapy to their baseline or to grade 
Prior treatment (non-alkylating agents) within  weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Must have recovered from the toxic effects of all prior chemotherapy
Patients must have been off of cytotoxic, immunosuppressive (except steroids), or targeted therapy, including standard and investigational treatments for AA, for at least  week or  half-lives whichever comes later, prior to entering this study, and have recovered from the toxic effects of that therapy to Grade  or less.
At the time of registration, patient must have recovered from the toxic effects of prior therapy to no more than grade  toxicity
Patients must have recovered (to Common Toxicity Criteria [CTC] version [v.]. =< grade  unless indicated below) from the acute toxic effects of all prior chemotherapy, immunotherapy prior to entering this study, with the exception of alopecia, weight changes and grade I or II lymphopenia
Must have recovered from toxic effects of prior chemotherapy
Treated with immunotherapeutic agents within  weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Treated with alkylating agents within  weeks before enrollment ( weeks for nitrosoureas) or treated within  week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapy
Prior chemotherapy (non-alkylating agents) within  weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Patients must have recovered from the toxic effects of prior therapy
Patients must have recovered from the toxic effects of any prior chemotherapy to < grade  (except for alopecia)
Patients who have not recovered from side effects of prior anti-cancer treatment to less than or equal to grade  toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.)  within the following time frames:\r\n* Received previous systemic therapy and has not recovered from side effects for more than  days prior to starting on treatment\r\n* Received previous radiation therapy and has not recovered from side effects for more than  days prior to starting on treatment\r\n* Received previous biologic therapy and has not recovered from side effects for more than  days prior to starting on treatment
No acute toxic effects from previous treatment superior to grade  at the start of the study
Prior radiation therapy is permitted as long as:\r\n* Recovered from the toxic effects of radiation treatment before study entry, except for alopecia
Patients must have been off of cytotoxic, immunosuppressive (except steroids), or targeted therapy for at least  weeks prior to entering this study, and have recovered from the toxic effects of that therapy to grade  or less
Recent prior therapy: systematic chemotherapy less than  weeks prior to infusion; exceptions:\r\n* There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such\r\n* Subjects receiving hydroxyurea or oral maintenance chemotherapy may be enrolled provided there has been no increase in dose for at least  weeks prior to starting apheresis or treatment\r\n* Subjects receiving steroid therapy at physiological replacement doses only are allowed provided there has been no increase in dose for at least  weeks prior to subject starting apheresis or treatment\r\n* Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion
Has not recovered from toxic effect of prior therapy to < Grade .
Greater than  weeks since last treatment (chemotherapy or radiation) provided subject has recovered from side effects of treatment prior to the study
Participants must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer directed therapy prior to study drug administration. If, after the required time frame, the numerical eligibility criteria are met, eg, blood count criteria, the participant is considered to have recovered adequately:
Have recovered from the acute effects of any prior systemic therapy.
Resolution of all acute toxic effects of previous anticancer therapy
Recovery from the effects of prior therapy:
Full recovery (< grade ) from the toxic effects of any earlier intervention and a minimum of  days from the administration of any investigational agent
Resolution of any toxic effects of previous therapies
Patients must have been off chemotherapy for  weeks prior to entering this study unless there is evidence of rapidly progressive disease. Patients must have recovered from the toxic effects of prior therapy to grade ?. The use of hydroxyurea is allowed to control counts up to  hrs prior to the start of therapy with AR-.
Recovered from all acute adverse effects of prior therapies, excluding alopecia (hair loss)
No chemotherapy, radiation, or major surgery within  weeks prior to first dose of study drug and recovered from toxic side effects of that therapy, unless treatment is indicated due to progressive disease.
Has not recovered to ? Grade  or baseline from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment.
Patients must have recovered from side effects resulting from prior cancer-directed therapy to a level of grade  or less (unless deemed not clinically significant by study investigator)
Subjects that have not recovered from side effects of previous therapy.
Participants must have recovered to grade  or  or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)
Subjects must have recovered from the toxic effects of any prior chemotherapy to =< grade  (except alopecia)
Patients must have recovered from the toxic effects of prior therapies (=< grade )
Patients who have not recovered to grade =<  or to their baseline from clinically significant adverse effects
Recovered from the toxic effects of all prior chemotherapy
Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion
Lack of recovery from toxic effects of previous treatment for RCC ? grade  with the exception of alopecia, unless stabilized under adequate medical control.
PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have recovered from any adverse effects from prior therapy (except alopecia) to =< CTCAE grade  prior to registration
Have received radiation therapy within  weeks (? weeks) prior to randomization or has not recovered from toxic effects of the treatment that was given > weeks prior to randomization.
Patients not recovered to Grade  or stabilized from the effects (excluding alopecia) of any prior therapy for their malignancies
Has not recovered to ? Grade  from toxic effects of prior therapy.
Has not recovered from toxic effects of prior therapy to ? Grade .
Recovery from the toxic effects of prior therapy, with a minimum time of:
Patient must have recovered from the acute toxic effects of the treatment before beginning study therapy.
Previous radiation therapy was allowed but must have been discontinued at least  months before study drug is administered, and the patient must have recovered from acute toxic effects
Radiation therapy completed at least  days prior to start of study treatment and patients must have recovered from any acute adverse effects.
Patients must have recovered from the toxic effects of prior therapies
Patients must have been off therapy for MDS for  weeks prior to entering this study, and must have recovered from the toxic effects of that therapy to at least grade , unless there is evidence of rapidly progressive disease; use of hydroxyurea (any dose) or cytarabine (ara-C) (up to  g/m^ x  doses) for patients with rapidly proliferative disease is allowed before the start of study therapy; these should be stopped for  hours prior to the initiation of azacitidine and sorafenib
Subjects must have recovered from the toxic effects of prior therapy; residual toxicity from any previous treatment must be =< Grade 
Has not recovered to ? Grade  from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.
Recovered from toxic effects attributed to UC- to grade  levels, or baseline
Participant has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.
Patients must have recovered from side effects from prior cancer-directed therapy to grade  or less (unless deemed not clinically significant by study investigator)
Treatment with any investigational agent within  days prior to registration for protocol therapy and the subject must have recovered from the acute toxic effects of the regimen.
Participants must have recovered to grade  or  or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)
History of prior malignancy, except for conditions as listed in the protocol if patients have recovered from the acute side effects incurred as a result of previous therapy
The patient has not recovered from the acute toxic effects of prior chemotherapy, radiation, or major surgery/significant trauma.
At the time of registration, patient must have recovered from the toxic effects of prior therapy to no more than grade  toxicity
No acute toxic effects from previous treatment superior to grade  at the start of the study
Patients must have recovered from the toxic effects of all prior therapy before entering this study
Patients must have been off chemotherapy for  weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade . Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.
Discontinued all prior cancer treatments for cancer & recovered from the acute effects of therapy
Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiation therapy prior to entry on study; patients must have had at least one prior treatment regimen; patients may have received treatment previously with cyclophosphamide topotecan or bevacizumab
(. continued) (such as presurgically for obtaining pharmacology data for the agent) will be eligible to enter the study provided they have recovered from the toxic effects of the agent if any. Any questions related to the definition of non-cytotoxic agents should be directed to the Study Chair.
Patients may be treated on this trial without having received prior therapy; if patients have received prior therapy, they must have recovered from all toxic effects prior to entering this study
Recovered from all toxic effects (excluding alopecia) of any prior anti-cancer therapy to Grade ?  or to the baseline laboratory values.
Received radiation (including therapeutic radioisotopes such as strontium ) therapy ?  months prior to the first dose of study treatment and have not recovered from side effects of such therapy (? Grade ) prior to the first dose of study treatment, except for alopecia.
Has not recovered from toxic effect of prior therapy to < Grade .
Resolution of all acute toxic effects of prior chemotherapy, and other cancer treatments
Patients must have recovered from side effects from prior cancer-directed therapy to grade  or less (unless deemed not clinically significant by study investigator)
Patient has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.
Use of an investigational agent that is not expected to be cleared by the time of first dose of study drug or that has been demonstrated to have prolonged side effects. Patients must have recovered from all side effects to a Grade  or  (except alopecia and neuropathy).
Have discontinued previous treatments for cancer and recovered from all acute toxic effects of prior systemic therapy (except alopecia) to grade ?;
Resolution of acute toxic effects of prior chemotherapy and other cancer treatments
Recovery from the toxic effects of prior therapy to not more than grade  or >  weeks from prior therapy to registration, whichever is later
Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or <= grade  prior to study entry.
Has not recovered to ? Grade  from toxic effects of prior therapy.
Patients must have been off all prior therapy for leukemia except hydroxyurea for  week prior to entering this study and recovered from the toxic effects of that therapy
At least  weeks should have elapsed since the last cycle of cytotoxic therapy or since the last dose of radiation therapy, at least  weeks must have elapsed since the patient has received any investigational therapy or antibodies, and at least  days since the last dose of biologics (i.e. rapamycin or sorafenib), and patients should have recovered from toxic side effects of previous therapy to a grade  or less, with the exception of the following:\r\n* Hematological toxicity: recovered to levels required above\r\n* Low electrolyte levels (such individuals should receive appropriate supplementation)\r\n* For patients on anticoagulant therapy or with pre-existing coagulation abnormalities, PT and partial thromboplastin time (PTT) must return to baseline\r\n* Liver function tests must resolve to values required above\r\n* Grade  hypoalbuminemia\r\n* Alopecia\r\n* Sterility
At the time of enrollment, at least  weeks and no more than  weeks should have elapsed since the last cycle of cytotoxic therapy or since the last dose of radiation therapy, and patients should have recovered from toxic side effects of previous therapy to a grade  or less, with the exception of the following:\r\n* Hematological toxicity: recovery to required levels\r\n* Low electrolyte levels (such individuals should receive appropriate supplementation)\r\n* For patients on anticoagulant therapy or with pre-existing coagulation abnormalities, PT, PTT must return to baseline\r\n* Liver function tests must resolve to required values\r\n* Grade  hypoalbuminemia is permitted\r\n* Alopecia is permitted\r\n* Sterility is permitted
Prior/Concurrent Therapy: Research participants must have recovered from the acute effects of prior treatment and:
Patients must have recovered from the toxic effects of prior therapy at the time of registration as follows:
Resolution of all clinically significant toxic effects of prior therapy.
Patient has recovered from the toxic effects of prior therapy, and is at least  days from the most recent cytotoxic therapy, prior to enrollment
At the time of registration, subjects must have recovered from the toxic effects of previous treatments, as determined by the treating physician.
Patients who have received prior adjuvant high dose interferon are allowed to participate as long as the last injection was given at least  days prior to the C-AMT PET scan and they have fully recovered from side effects (i.e., grade =<  or permanent side effects that require hormone replacement therapy)
Prior therapy: Must have recovered from acute toxic effects of prior anti-cancer therapy (durations relative to date of enrollment):
Has not recovered to ? Grade  from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.
Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.
Has not recovered to ? Grade  from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy
